The B sample of blood taken from Jonathan “Jock” Paget’s mount, Clifton Promise, will undergo analysis in mid-November.
The A sample taken from the horse as part of routine testing after his victory at the Burghley International Horse Trials tested positive for the long-acting sedative, reserpine.
Resperine is listed on the FEI’s Clean Sport database as a prohibited substance. It is classed as a tranquiliser, and is an alkaloid used for long-term sedation in horses.
Equestrian Sports New Zealand (ESNZ) said today that it had received notification from the FEI that the analysis of the B sample would occur in mid-November, with the results notified to the New Zealand body and the rider in due course.
The timescale was a normal part of the legal process currently under way, ESNZ said in a brief statement. “You will appreciate that neither Jock nor ESNZ can make further comment at this stage.”
Paget remains provisionally suspended from any national or international competition and Clifton Promise is serving a provisional two-month suspension, pending the B sample and any subsequent hearings.
When news of the positive A sample broke in mid-October, Paget expressed his shock at the reserpine finding, saying he could not understand how the drug came to be in the horse’s system.
Clifton Eventers, who supplies Paget with his mounts, has voiced its support for Paget and is supporting him in preparation for an FEI disciplinary tribunal hearing, should the B sample prove positive for the drug.